GlobalData on MSN8d
OS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patients
The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...
OS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trial
OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention ...
OS Therapies price target raised to $15 from $8 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The ...
OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital
OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a ...
Pilot study highlights critical gaps in patients' osteoporosis awareness and management
Although osteoporosis and related fractures impose a significant and growing burden, the management of this disease, even ...
Medscape19d
Bisphosphonate Use Linked to Increased Risk for Acute Angle Closure in Patients With Osteoporosis
“The results from our study will have important public health implications as millions of patients around the world use bisphosphonates for osteoporosis treatment,” the authors of the study wrote.